Tavapadon (Juvmo) is the first selective D1/D5 dopamine receptor agonist approved for adult Parkinson disease, positioning a mechanistically differentiated oral, once-daily dopaminergic strategy.

Baricitinib is now FDA approved for adolescents 12 and older with severe alopecia areata, extending the once-daily pill ...

This interview has been lightly edited for clarity.

Chronic hand eczema commonly reflects overlapping irritant, allergic, atopic, and protein-driven mechanisms, making patch ...

Tampa General Hospital and Moffitt Cancer Center are both racing to expand outpatient capacity, from added observation bays ...

Employers can improve access to cancer care and address rising costs by pairing existing benefits with targeted strategies, ...

This commentary discusses the current prior authorization (PA) process and the negative impacts it can have on patient care. According to the American Medical Association, 94% of patients experience ...

The Inflation Reduction Act will likely change incentives surrounding single-indication launches and postapproval research for additional indications in small molecule drugs, affecting patient access.

Advanced primary care may be one of employers' strongest tools for catching cancer earlier, and better support during and ...

Debra Patt, MD, PhD, MBA, MPH, discusses how AI can streamline prior authorization and revenue cycle workflows in community ...

The rapid expansion of cell and gene therapies and other very high-cost drugs may give value-based contracting a second life, ...

Yesterday, September 24, the FDA approved the combination of belzutifan (WELIREG; Merck) plus lenvatinib (LENVIMA; Eisai) to ...